Vicore Pharma Holding AB

NASDAQ:VCRE

Medical - Pharmaceuticals

Healthcare
$9.90 -1.66%

-$0.24 today

Market cap
$279.65M
Beta
0.15

Volume 0.00M

Average 0.26M

VCRE Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Vicore Pharma Holding ABNASDAQ: VCRE

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares growth accelerates

Q2 FY2026 weighted avg shares of 280.09M shares rose 1094.0% year over year, ahead of the +51.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 894.9% from the prior quarter. Over 3 fiscal years it compounded at +47.9% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +1094.0% holds above the trailing-twelve-month pace of +51.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
280.09M+894.9% QoQ
Last fiscal yearDec 2025
23.99M+75.3% YoY
LTMJun 2026
142.11M+51.7% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1094.0%——
1 year+75.3%——
3-year CAGR+47.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
23.99M SEK
Year-over-year change
+75.3%
4-year CAGR
-23.4%

Weighted Avg Shares vs competitors

How VCRE compares with its peers on the latest reported figures

  • VCRE's LTM Jun 2026 weighted avg shares of 142.11M shares is the highest of the 2 companies compared; the peer median is 87.58M shares.
  • Its year-over-year change of +51.7% is the highest of 2, against a peer median of +5.0%.
  • Over three fiscal years its annual growth of +47.9% compares with a peer median of +12.2%.
VCRE Competitors Peer median
Weighted Avg Shares for VCRE and competitors
Company Period LTM YoY 3-year CAGR
VCREVicore Pharma Holding ABLTM Jun 2026142.11M +51.7%+47.9%
LQDALiquidia CorporationLTM Jun 202687.58M +5.0%+12.2%
AVLNAvalyn Pharma Inc. Common Stock—— ——
Peer median (excluding VCRE) 87.58M+5.0%+12.2%

Competitors are the stored peer set for VCRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

SEK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000109.35M3.82M
Cost of Revenue3.58M0000
Gross Profit(3.58M)00109.35M3.82M
Gross Margin———100.0%100.0%
Research & Development30.05M249.97M276.29M249.26M390.35M
Selling, General & Admin2.39M37.53M44.6M50.44M67.91M
Operating Expenses32.59M290.73M321.51M299.71M458.26M
Depreciation & Amortization371.33K3.61M3.42M2.24M0
EBITDA(32.07M)(285.19M)(307.9M)(166.64M)(477.41M)
EBITDA Margin———-152.4%-12507.6%
Operating Income(32.59M)(290.73M)(321.51M)(190.36M)(454.45M)
Operating Margin———-174.1%-11905.8%
Interest Income70.2K913K10.54M21.08M23.89M
Interest Expense08K2K8K60K
Other Income / Expenses(211.92K)1.92M10.18M21.47M(23.03M)
Income Before Tax(32.8M)(288.81M)(311.33M)(168.89M)(477.47M)
Pre-Tax Margin———-154.5%-12509.1%
Income Tax Expense(252.7K)(384K)(384K)(256K)0
Net Income(294.97M)(288.42M)(310.94M)(168.63M)(477.47M)
Net Margin———-154.2%-12509.1%
EPS (Basic)(0.47)(38.82)(31.80)(12.30)(19.90)
EPS (Diluted)(0.47)(38.82)(31.80)(12.30)(19.90)
Weighted Avg Shares69.68M7.42M9.66M13.68M23.99M
Weighted Avg Shares (Diluted)69.68M7.42M9.66M13.68M23.99M

Vicore Pharma Holding AB

NASDAQ:VCRE

Intrinsic Alpha fair value

Locked

Current Price

$9.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.